United Therapeutics Corporation announced the expansion of its license and collaboration agreement with MannKind Corporation to develop a second dry powder inhalation therapy. This expansion follows the success of their initial collaboration, which led to the FDA approval of Tyvaso DPI.
Under the amended agreement, United Therapeutics exercised its option to develop this new product, which will utilize MannKind’s proprietary Technosphere platform. This move triggers a $5 million upfront payment to MannKind, with potential for up to $35 million in additional development milestones and future royalties.
This strategic expansion highlights United Therapeutics' commitment to leveraging advanced drug delivery technologies to enhance its pipeline and address unmet medical needs. The development of a second inhaled therapy could further diversify the company's product offerings and strengthen its position in the pulmonary market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.